News
PRQR
2.100
-1.87%
-0.040
Evercore ISI Remains a Buy on ProQR (PRQR)
TipRanks · 14h ago
Weekly Report: what happened at PRQR last week (1208-1212)?
Weekly Report · 3d ago
Positive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation
TipRanks · 12/10 13:45
Weekly Report: what happened at PRQR last week (1201-1205)?
Weekly Report · 12/08 09:02
ProQR Therapeutics to Participate in Evercore Healthcare Conference
Reuters · 12/01 13:00
Weekly Report: what happened at PRQR last week (1124-1128)?
Weekly Report · 12/01 09:02
Weekly Report: what happened at PRQR last week (1117-1121)?
Weekly Report · 11/24 09:02
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading
NASDAQ · 11/24 04:30
ProQR Therapeutics Reports Q3 2025 Financial Results
TipRanks · 11/21 03:52
Weekly Report: what happened at PRQR last week (1110-1114)?
Weekly Report · 11/17 09:02
Weekly Report: what happened at PRQR last week (1103-1107)?
Weekly Report · 11/10 09:02
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 11/07 01:31
ProQR GAAP EPS of -€0.10, revenue of €2.88M
Seeking Alpha · 11/06 12:48
ProQR Reports Q3 2025 Financial Results Amid Revenue Decline
TipRanks · 11/06 12:42
ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year
TipRanks · 11/06 12:21
ProQR Q3 revenue misses estimates, reports net loss
Reuters · 11/06 12:07
ProQR Therapeutics reports Q3 cash position of €106.9 million and initiates Phase 1 trial of AX-0810
Reuters · 11/06 12:01
PROQR THERAPEUTICS Q3 EPS EUR -0.1
Reuters · 11/06 12:00
ProQR (PRQR) Receives a Buy from Evercore ISI
TipRanks · 11/05 06:16
ProQR Positioned for Growth: Strategic Advancements and Clinical Milestones in RNA Editing
TipRanks · 11/04 15:05
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).